-
China’s NHC Advances Enhanced Recovery After Surgery (ERAS) Protocols Nationwide
•
The National Health Commission (NHC) has released a notification with the goal of promoting enhanced recovery after surgery (ERAS) services across China. ERAS, as defined by the American Association of Nurse Anesthesiology, is a patient-centered, evidence-based approach developed by multidisciplinary teams for a surgical specialty and facility. The focus is…
-
ChengDu ShengNuo Biotech Secures NMPA Approval for Generic Firazyr Equivalent
•
ChengDu ShengNuo Biotech Co., Ltd (SHA: 688117), a China-based polypeptide specialist, has announced that it has received marketing approval from the National Medical Products Administration (NMPA) for its generic version of Shire’s Firazyr (icatibant). This marks a significant milestone as the company becomes the first manufacturer to file for Drug…
-
CanSino Biotechnology Leads RMB 500 Million Private Equity Fund for Vaccine Investments
•
China-based vaccines specialist CanSino Biotechnology Inc., (HKG: 6185) has announced plans to invest RMB 140 million (USD 20.3 million) in the establishment of a private equity fund with a total value of RMB 500 million (USD 72.5 million). The fund will focus on investments in vaccine companies, highlighting CanSino’s commitment…
-
PharmaEssentia Corporation Completes Secondary Offering of GDR Shares on Luxembourg Exchange
•
Taiwan-based PharmaEssentia Corporation (TPE: 6446) has announced the successful closing of a secondary offering of Global Depositary Receipt (GDR) shares. A total of 34 million shares of common stock were offered at a price of USD 13.61 per share, resulting in a capital raise of USD 462.7 million. The shares…
-
Lee’s Pharmaceutical Holdings Ltd Reports 2022 Revenues and Pipeline Updates
•
China-based Lee’s Pharmaceutical Holdings Ltd (HKG: 0950) has released its 2022 financial report, recording HKD 1.233 billion (USD 157 million) in revenues, marking a 2.6% year-on-year (YOY) decrease. In-licensed products contributed HKD 733 million (USD 93.73 million), accounting for 59.5% of total revenues, while patented drugs and generics made up…
-
Reistone Biopharma’s RSS0343 Receives NMPA Approval for Non-Cystic Fibrosis Bronchiectasis
•
Reistone Biopharma Co., Ltd, a company incubated by Hengrui Pharmaceuticals (SHA: 600276) with an investment of USD 100 million in 2018, has obtained clinical trial approval from the National Medical Products Administration (NMPA) for its Category 1 drug, RSS0343, intended to treat non-cystic fibrosis bronchiectasis (NCFB). Understanding Non-Cystic Fibrosis Bronchiectasis…
-
Siemens Healthineers and China Chest Pain Center Launch Smart Training Program
•
German healthcare giant Siemens Healthineers (ETR: SHL) has partnered with the China Chest Pain Center to launch the “Rising Star smart chest pain center standardized construction training program.” This initiative is designed to enhance the standardized construction of chest pain treatment processes and improve clinical intervention diagnosis and treatment capabilities.…
-
Neurodawn Pharmaceutical’s Y-1 Receives NMPA Approval for Primary Intracranial Tumor Treatment
•
Nanjing-based Neurodawn Pharmaceutical Co., Ltd has announced that its Category 1 drug, injectable Y-1, has obtained clinical trial approval from the National Medical Products Administration (NMPA) for the treatment of primary intracranial malignant tumors. TRPML1 Inhibitor’s Non-Clinical Study ResultsNon-clinical studies have demonstrated that the TRPML1 inhibitor, Y-1, can effectively inhibit…
